Annual D&A
$97.03 M
+$11.48 M+13.42%
31 December 2023
Summary:
Alnylam Pharmaceuticals annual depreciation & amortization is currently $97.03 million, with the most recent change of +$11.48 million (+13.42%) on 31 December 2023. During the last 3 years, it has risen by +$22.60 million (+30.36%). ALNY annual D&A is now at all-time high.ALNY Depreciation And Amortization Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Quarterly D&A
$27.04 M
+$2.35 M+9.50%
30 September 2024
Summary:
Alnylam Pharmaceuticals quarterly depreciation & amortization is currently $27.04 million, with the most recent change of +$2.35 million (+9.50%) on 30 September 2024. Over the past year, it has increased by +$3.51 million (+14.90%). ALNY quarterly D&A is now -16.61% below its all-time high of $32.42 million, reached on 30 June 2021.ALNY Quarterly D&A Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
TTM D&A
$101.19 M
+$3.51 M+3.59%
30 September 2024
Summary:
Alnylam Pharmaceuticals TTM depreciation & amortization is currently $101.19 million, with the most recent change of +$3.51 million (+3.59%) on 30 September 2024. Over the past year, it has increased by +$3.25 million (+3.31%). ALNY TTM D&A is now at all-time high.ALNY TTM D&A Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
ALNY Depreciation And Amortization Performance
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | +13.4% | +14.9% | +3.3% |
| 3 y3 years | +30.4% | +16.4% | +13.5% |
| 5 y5 years | +536.4% | +102.9% | +106.4% |
ALNY Depreciation And Amortization High & Low
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3 years | at high | +30.4% | at high | +36.7% | at high | +23.2% |
| 5 y | 5 years | at high | +536.4% | -16.6% | +114.6% | at high | +106.4% |
| alltime | all time | at high | >+9999.0% | -16.6% | >+9999.0% | at high | >+9999.0% |
Alnylam Pharmaceuticals Depreciation And Amortization History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sept 2024 | - | $27.04 M(+9.5%) | $101.19 M(+3.6%) |
| June 2024 | - | $24.69 M(-3.1%) | $97.68 M(+1.3%) |
| Mar 2024 | - | $25.49 M(+6.3%) | $96.44 M(-0.6%) |
| Dec 2023 | $97.03 M(+13.4%) | $23.97 M(+1.9%) | $97.03 M(-0.9%) |
| Sept 2023 | - | $23.53 M(+0.4%) | $97.94 M(+3.0%) |
| June 2023 | - | $23.45 M(-10.1%) | $95.06 M(+3.5%) |
| Mar 2023 | - | $26.08 M(+4.8%) | $91.85 M(+7.4%) |
| Dec 2022 | $85.55 M(-4.6%) | $24.89 M(+20.5%) | $85.55 M(+4.2%) |
| Sept 2022 | - | $20.65 M(+2.0%) | $82.12 M(-3.0%) |
| June 2022 | - | $20.24 M(+2.3%) | $84.69 M(-12.6%) |
| Mar 2022 | - | $19.78 M(-7.8%) | $96.87 M(+8.0%) |
| Dec 2021 | $89.69 M(+20.5%) | $21.45 M(-7.6%) | $89.69 M(+0.6%) |
| Sept 2021 | - | $23.22 M(-28.4%) | $89.12 M(+5.3%) |
| June 2021 | - | $32.42 M(+157.3%) | $84.67 M(+20.9%) |
| Mar 2021 | - | $12.60 M(-39.7%) | $70.03 M(-5.9%) |
| Dec 2020 | $74.44 M(+36.9%) | $20.88 M(+11.2%) | $74.44 M(+9.0%) |
| Sept 2020 | - | $18.77 M(+5.6%) | $68.32 M(+8.7%) |
| June 2020 | - | $17.78 M(+4.5%) | $62.87 M(+9.8%) |
| Mar 2020 | - | $17.01 M(+15.2%) | $57.28 M(+5.4%) |
| Dec 2019 | $54.37 M(+256.6%) | $14.76 M(+10.8%) | $54.37 M(+10.9%) |
| Sept 2019 | - | $13.33 M(+9.4%) | $49.03 M(+35.8%) |
| June 2019 | - | $12.19 M(-13.5%) | $36.11 M(+38.0%) |
| Mar 2019 | - | $14.09 M(+49.5%) | $26.16 M(+71.6%) |
| Dec 2018 | $15.25 M(+28.2%) | $9.43 M(+2227.4%) | $15.25 M(+89.0%) |
| Sept 2018 | - | $405.00 K(-81.9%) | $8.07 M(-28.3%) |
| June 2018 | - | $2.24 M(-29.5%) | $11.25 M(-6.8%) |
| Mar 2018 | - | $3.18 M(+41.6%) | $12.08 M(+1.5%) |
| Dec 2017 | $11.90 M(-21.4%) | $2.25 M(-37.4%) | $11.90 M(-6.1%) |
| Sept 2017 | - | $3.59 M(+17.0%) | $12.67 M(+0.7%) |
| June 2017 | - | $3.07 M(+2.2%) | $12.58 M(-7.0%) |
| Mar 2017 | - | $3.00 M(-0.6%) | $13.53 M(-10.6%) |
| Dec 2016 | $15.13 M(-20.6%) | $3.02 M(-13.8%) | $15.13 M(-11.9%) |
| Sept 2016 | - | $3.50 M(-12.7%) | $17.18 M(-9.3%) |
| June 2016 | - | $4.01 M(-12.8%) | $18.95 M(-5.1%) |
| Mar 2016 | - | $4.60 M(-9.2%) | $19.96 M(+4.8%) |
| Dec 2015 | $19.05 M(+59.7%) | $5.07 M(-3.8%) | $19.05 M(+10.0%) |
| Sept 2015 | - | $5.27 M(+5.0%) | $17.32 M(+14.2%) |
| June 2015 | - | $5.02 M(+36.1%) | $15.17 M(+16.5%) |
| Mar 2015 | - | $3.69 M(+10.4%) | $13.02 M(+9.1%) |
| Dec 2014 | $11.93 M | $3.34 M(+7.2%) | $11.93 M(+6.4%) |
| Sept 2014 | - | $3.12 M(+8.7%) | $11.21 M(+3.3%) |
| June 2014 | - | $2.87 M(+10.3%) | $10.86 M(+1.5%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Mar 2014 | - | $2.60 M(-1.0%) | $10.70 M(+4.6%) |
| Dec 2013 | $10.23 M(+13.2%) | $2.63 M(-5.0%) | $10.23 M(+6.3%) |
| Sept 2013 | - | $2.76 M(+2.0%) | $9.63 M(+5.2%) |
| June 2013 | - | $2.71 M(+27.5%) | $9.15 M(+1.2%) |
| Mar 2013 | - | $2.13 M(+5.1%) | $9.04 M(+0.1%) |
| Dec 2012 | $9.04 M(+76.3%) | $2.02 M(-11.4%) | $9.04 M(+9.5%) |
| Sept 2012 | - | $2.29 M(-12.3%) | $8.25 M(+14.2%) |
| June 2012 | - | $2.60 M(+22.8%) | $7.22 M(+22.3%) |
| Mar 2012 | - | $2.12 M(+71.5%) | $5.91 M(+15.3%) |
| Dec 2011 | $5.13 M(+3.7%) | $1.24 M(-2.0%) | $5.13 M(-1.0%) |
| Sept 2011 | - | $1.26 M(-1.9%) | $5.18 M(-0.1%) |
| June 2011 | - | $1.29 M(-3.9%) | $5.18 M(+1.3%) |
| Mar 2011 | - | $1.34 M(+3.7%) | $5.12 M(+3.6%) |
| Dec 2010 | $4.94 M(-17.5%) | $1.29 M(+2.0%) | $4.94 M(+3.2%) |
| Sept 2010 | - | $1.27 M(+3.5%) | $4.79 M(+3.3%) |
| June 2010 | - | $1.22 M(+5.3%) | $4.63 M(-13.5%) |
| Mar 2010 | - | $1.16 M(+2.2%) | $5.35 M(-10.7%) |
| Dec 2009 | $5.99 M(+4.6%) | $1.14 M(+2.3%) | $5.99 M(-9.9%) |
| Sept 2009 | - | $1.11 M(-42.8%) | $6.65 M(-7.2%) |
| June 2009 | - | $1.94 M(+7.8%) | $7.17 M(+9.1%) |
| Mar 2009 | - | $1.80 M(+0.2%) | $6.58 M(+14.9%) |
| Dec 2008 | $5.73 M(+40.3%) | $1.80 M(+10.2%) | $5.73 M(+18.6%) |
| Sept 2008 | - | $1.63 M(+21.2%) | $4.83 M(+13.7%) |
| June 2008 | - | $1.35 M(+41.5%) | $4.25 M(+10.7%) |
| Mar 2008 | - | $951.00 K(+5.4%) | $3.84 M(-6.0%) |
| Dec 2007 | $4.08 M(+7.0%) | $902.00 K(-13.9%) | $4.08 M(-4.3%) |
| Sept 2007 | - | $1.05 M(+11.8%) | $4.27 M(-15.8%) |
| June 2007 | - | $937.00 K(-21.6%) | $5.07 M(+20.1%) |
| Mar 2007 | - | $1.20 M(+9.9%) | $4.22 M(+10.6%) |
| Dec 2006 | $3.81 M(+22.3%) | $1.09 M(-41.3%) | $3.81 M(+9.6%) |
| Sept 2006 | - | $1.85 M(+2003.4%) | $3.48 M(+46.9%) |
| June 2006 | - | $88.00 K(-88.8%) | $2.37 M(-26.7%) |
| Mar 2006 | - | $789.00 K(+4.9%) | $3.23 M(+3.7%) |
| Dec 2005 | $3.12 M(+27.6%) | $752.00 K(+1.6%) | $3.12 M(+0.0%) |
| Sept 2005 | - | $740.00 K(-22.3%) | $3.12 M(+0.4%) |
| June 2005 | - | $952.00 K(+41.0%) | $3.11 M(+19.1%) |
| Mar 2005 | - | $675.00 K(-10.1%) | $2.61 M(+6.7%) |
| Dec 2004 | $2.44 M(+191.6%) | $751.00 K(+3.2%) | $2.44 M(+44.4%) |
| Sept 2004 | - | $728.00 K(+60.4%) | $1.69 M(+75.4%) |
| June 2004 | - | $454.00 K(-11.2%) | $965.00 K(+88.8%) |
| Mar 2004 | - | $511.00 K | $511.00 K |
| Dec 2003 | $838.00 K(+2227.8%) | - | - |
| Dec 2002 | $36.00 K | - | - |
FAQ
- What is Alnylam Pharmaceuticals annual depreciation & amortization?
- What is the all time high annual D&A for Alnylam Pharmaceuticals?
- What is Alnylam Pharmaceuticals annual D&A year-on-year change?
- What is Alnylam Pharmaceuticals quarterly depreciation & amortization?
- What is the all time high quarterly D&A for Alnylam Pharmaceuticals?
- What is Alnylam Pharmaceuticals quarterly D&A year-on-year change?
- What is Alnylam Pharmaceuticals TTM depreciation & amortization?
- What is the all time high TTM D&A for Alnylam Pharmaceuticals?
- What is Alnylam Pharmaceuticals TTM D&A year-on-year change?
What is Alnylam Pharmaceuticals annual depreciation & amortization?
The current annual D&A of ALNY is $97.03 M
What is the all time high annual D&A for Alnylam Pharmaceuticals?
Alnylam Pharmaceuticals all-time high annual depreciation & amortization is $97.03 M
What is Alnylam Pharmaceuticals annual D&A year-on-year change?
Over the past year, ALNY annual depreciation & amortization has changed by +$11.48 M (+13.42%)
What is Alnylam Pharmaceuticals quarterly depreciation & amortization?
The current quarterly D&A of ALNY is $27.04 M
What is the all time high quarterly D&A for Alnylam Pharmaceuticals?
Alnylam Pharmaceuticals all-time high quarterly depreciation & amortization is $32.42 M
What is Alnylam Pharmaceuticals quarterly D&A year-on-year change?
Over the past year, ALNY quarterly depreciation & amortization has changed by +$3.51 M (+14.90%)
What is Alnylam Pharmaceuticals TTM depreciation & amortization?
The current TTM D&A of ALNY is $101.19 M
What is the all time high TTM D&A for Alnylam Pharmaceuticals?
Alnylam Pharmaceuticals all-time high TTM depreciation & amortization is $101.19 M
What is Alnylam Pharmaceuticals TTM D&A year-on-year change?
Over the past year, ALNY TTM depreciation & amortization has changed by +$3.25 M (+3.31%)